$3.45
-0.13 (-3.63%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CANF is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
22 interventional · 11 with posted results
Held by 1 tracked-famous manager (CITADEL ADVISORS LLC) · FINRA short interest 1.6 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and EfficacyNCT06643260Proportion of subjects who achieve a Psoriasis Area and Severity Index (PASI) score response of ≥75% (PASI 75)Randomized · Quadruple-masked · Treatment | Phase 3 | Not yet recruiting | Drug: piclidenoson, Placebo | Plaque Psoriasis | 705 | Dec 2027 | ≤ 499 d | 2025-04-29 |
| An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe SyndromeNCT0741045599mTc-DMSAOpen-label · Treatment | Phase 2 | Not yet recruiting | Drug: Piclidenoson | Lowe Syndrome | 5 | 2027-08-31 | in 377 d | 2026-02-18 |
| Namodenoson Treatment of Advanced Pancreatic CancerNCT06387342Adverse EventsOpen-label · Treatment | Phase 2 | Recruiting | Drug: Namodenoson 25mg | Pancreatic Adenocarcinoma, Pancreatic Cancer | 20 | 2026-07-15 | — | 2025-01-31 |
| Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 CirrhosisNCT05201404Overall Survival (OS)Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Namodenoson, Placebo | Hepatocellular Carcinoma, Cirrhosis | 471 | Feb 2026 | — | 2025-04-29 |
| Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)NCT04697810Non-Alcoholic Fatty Liver Disease (NAFLD) activity score (NAS)Randomized · Quadruple-masked · Treatment | Phase 2 | Unknown status | Drug: Namodenoson, Placebo | NASH - Nonalcoholic Steatohepatitis | 114 | 2025-04-15 | — | 2024-07-31 |
| Piclidenoson for Treatment of COVID-19NCT04333472Proportion of subjects alive and free of respiratory failureRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Piclidenoson, Placebo | COVID-19, Coronavirus Infection | 6 | 2022-03-06actual | — | 2022-04-22 |
| CF101 Therapy in Patients With Moderate-to-severe Plaque PsoriasisNCT03168256Psoriasis Area and Severity Index (PASI) score response of ≥75% (PASI 75) at Week 16Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: CF101 2mg, CF101 3mg, Apremilast 30mg, Placebo Oral Tablet | Plaque Psoriasis | 528 | 2022-01-06actual | — | 2022-06-28 |
| CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid ArthritisNCT02647762Efficacy of oral CF101, BID for 12 weeks to subjects with active rheumatoid arthritis (RA) relative to oral methotrexate (MTX) as assessed by the proportion of subjects achieving a Disease Activity Score (DAS) of Low Disease Activity (LDA)Randomized · Quadruple-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Interim analysis results | Drug: CF101 1 mg, CF101 2 mg, Placebo, MTX | Rheumatoid Arthritis | 244 | 2020-11-30actual | — | 2020-12-19 |
| A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver DiseaseNCT02927314Efficacy of CF102 as determined by change in serum alanine aminotransferase (ALT) levelsRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: CF102, Placebo | Non-alcoholic Steatohepatitis (NASH) | 60 | 2020-03-01actual | — | 2020-03-17 |
| Safety &Efficacy of CF101 to Subjects With UveitisNCT01905124Severity of uveitis on standardized photographic assessmentRandomized · Quadruple-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: The company has decided not to conduct the study | Drug: CF101, Placebo | Uveitis, Posterior, Uveitis, Intermediate | 0 | Sep 2019 | — | 2018-02-01 |
| A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the KneeNCT00837291Proportion of responders by OMERACT-OARSI definitionRandomized · Quadruple-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: The company has decided not to conduct the study | Drug: CF101, Placebo | Osteoarthritis of the Knee | 0 | Dec 2018 | — | 2018-02-01 |
| Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)NCT02128958results2021-12-29Number of Subjects With Overall SurvivalRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: CF102, Placebo | Hepatocellular Carcinoma | 78 | 2017-11-27actual | — | 2022-10-04 |
| Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular PressureNCT01033422results2019-05-23Intraocular Pressure in mmHgRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: CF101, Placebo for | Ocular Hypertension, Glaucoma | 89 | Dec 2016actual | — | 2022-05-12 |
| Trial of CF101 to Treat Patients With PsoriasisNCT01265667results2017-09-20Number of Subjects Achieving Psoriasis Area and Severity Index (PASI) 75 at 12 WeeksRandomized · Quadruple-masked · Treatment | Phase 2/3 | Completed | Drug: CF101, Placebo | Plaque Psoriasis | 293 | Mar 2015actual | — | 2020-11-18 |
| Oral CF101 Tablets Treatment in Patients With Rheumatoid ArthritisNCT01034306results2015-03-09Number of Subjects Achieving an American College of Rheumatology 20 (ACR20) Response (20% Improvement)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: CF101, Placebo control | Rheumatoid Arthritis | 79 | Dec 2013actual | — | 2022-05-24 |
| Trial of CF101 to Treat Patients With Dry Eye DiseaseNCT01235234results2015-03-11Number of Subjects Who Achieved Complete Clearing of Corneal Staining (i.e., Total Corneal FS Score = 0) at Week 24Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: CF101 | Keratoconjunctivitis Sicca | 236 | Nov 2013actual | — | 2022-06-30 |
| A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular CarcinomaNCT00790218results2015-02-27Dose Limiting ToxicityNon-randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: CF102 | Hepatocellular Carcinoma | 19 | Dec 2012actual | — | 2022-05-17 |
| A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1NCT00790673results2015-04-15Adverse Event Profile of Repeated Dosing of CF102Randomized · Quadruple-masked · Treatment | Phase 1/2 | Completed | Drug: CF 102, Placebo | Chronic Hepatitis C | 32 | Jun 2011actual | — | 2015-04-15 |
| Safety and Efficacy Study of CF101 to Treat PsoriasisNCT00428974results2011-09-26Change From Baseline (CFB) in Psoriasis Area and Severity Index (PASI) ScoreRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: CF101 1mg, CF101 2mg, CF101 4mg, Placebo | Plaque Psoriasis | 76 | Sep 2009actual | — | 2023-02-08 |
| Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis SiccaNCT00349466results2011-08-12Change From Baseline to Week 12 in Schirmer Test (ST) Score in MillimetersRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: CF101, Placebo | Keratoconjunctivitis Sicca | 80 | May 2009actual | — | 2022-05-09 |
| Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis PatientsNCT00556894results2015-03-09ACR20 at Week 12Randomized · Quadruple-masked · Prevention | Phase 2 | Completed | Drug: CF101, Placebo | Rheumatoid Arthritis | 253 | Mar 2009actual | — | 2018-03-29 |
| Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis PatientsNCT00280917results2015-03-17ACR Efficacy CriteriaTriple-masked · Treatment | Phase 2 | Completed | Drug: CF101 | Rheumatoid Arthritis | 254 | Apr 2007actual | — | 2023-09-18 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19